171 related articles for article (PubMed ID: 36961000)
21. Uptake of KRAS Testing and Anti-EGFR Antibody Use for Colorectal Cancer in the VA.
Becker DJ; Lee KM; Lee SY; Lynch KE; Makarov DV; Sherman SE; Morrissey CD; Kelley MJ; Lynch JA
JCO Precis Oncol; 2021; 5():. PubMed ID: 34250412
[TBL] [Abstract][Full Text] [Related]
22.
Wardak M; Sonni I; Fan AP; Minamimoto R; Jamali M; Hatami N; Zaharchuk G; Fischbein N; Nagpal S; Li G; Koglin N; Berndt M; Bullich S; Stephens AW; Dinkelborg LM; Abel T; Manning HC; Rosenberg J; Chin FT; Gambhir SS; Mittra ES
Radiology; 2022 Jun; 303(3):620-631. PubMed ID: 35191738
[TBL] [Abstract][Full Text] [Related]
23. Relationship Between 18F-FDG PET/CT Scans and KRAS Mutations in Metastatic Colorectal Cancer.
Kawada K; Toda K; Nakamoto Y; Iwamoto M; Hatano E; Chen F; Hasegawa S; Togashi K; Date H; Uemoto S; Sakai Y
J Nucl Med; 2015 Sep; 56(9):1322-7. PubMed ID: 26135109
[TBL] [Abstract][Full Text] [Related]
24. Using tumor habitat-derived radiomic analysis during pretreatment
Zhao H; Su Y; Wang Y; Lyu Z; Xu P; Gu W; Tian L; Fu P
Cancer Imaging; 2024 Feb; 24(1):26. PubMed ID: 38342905
[TBL] [Abstract][Full Text] [Related]
25. Regulation of 18F-FDG accumulation in colorectal cancer cells with mutated KRAS.
Iwamoto M; Kawada K; Nakamoto Y; Itatani Y; Inamoto S; Toda K; Kimura H; Sasazuki T; Shirasawa S; Okuyama H; Inoue M; Hasegawa S; Togashi K; Sakai Y
J Nucl Med; 2014 Dec; 55(12):2038-44. PubMed ID: 25453050
[TBL] [Abstract][Full Text] [Related]
26.
Zhou R; Choi H; Cao J; Pantel A; Gupta M; Lee HS; Mankoff D
J Nucl Med; 2023 Jan; 64(1):131-136. PubMed ID: 35772960
[TBL] [Abstract][Full Text] [Related]
27. Role of [¹⁸F]FDG PET in prediction of KRAS and EGFR mutation status in patients with advanced non-small-cell lung cancer.
Caicedo C; Garcia-Velloso MJ; Lozano MD; Labiano T; Vigil Diaz C; Lopez-Picazo JM; Gurpide A; Zulueta JJ; Richter Echevarria JA; Perez Gracia JL
Eur J Nucl Med Mol Imaging; 2014 Nov; 41(11):2058-65. PubMed ID: 24990403
[TBL] [Abstract][Full Text] [Related]
28. Exploratory Clinical Investigation of (4S)-4-(3-18F-Fluoropropyl)-L-Glutamate PET of Inflammatory and Infectious Lesions.
Chae SY; Choi CM; Shim TS; Park Y; Park CS; Lee HS; Lee SJ; Oh SJ; Kim SY; Baek S; Koglin N; Stephens AW; Dinkelborg LM; Moon DH
J Nucl Med; 2016 Jan; 57(1):67-9. PubMed ID: 26471694
[TBL] [Abstract][Full Text] [Related]
29. A small molecule approach to degrade RAS with EGFR repression is a potential therapy for KRAS mutation-driven colorectal cancer resistance to cetuximab.
Lee SK; Cho YH; Cha PH; Yoon JS; Ro EJ; Jeong WJ; Park J; Kim H; Il Kim T; Min DS; Han G; Choi KY
Exp Mol Med; 2018 Nov; 50(11):1-12. PubMed ID: 30459318
[TBL] [Abstract][Full Text] [Related]
30. Imaging the Tumor Antioxidant Response with [
Timmermand OV; Witney TH
Methods Mol Biol; 2024; 2729():233-249. PubMed ID: 38006500
[TBL] [Abstract][Full Text] [Related]
31. Pilot Preclinical and Clinical Evaluation of (4S)-4-(3-[18F]Fluoropropyl)-L-Glutamate (18F-FSPG) for PET/CT Imaging of Intracranial Malignancies.
Mittra ES; Koglin N; Mosci C; Kumar M; Hoehne A; Keu KV; Iagaru AH; Mueller A; Berndt M; Bullich S; Friebe M; Schmitt-Willich H; Gekeler V; Fels LM; Bacher-Stier C; Moon DH; Chin FT; Stephens AW; Dinkelborg LM; Gambhir SS
PLoS One; 2016; 11(2):e0148628. PubMed ID: 26890637
[TBL] [Abstract][Full Text] [Related]
32. Prognostic and predictive biomarkers for anti-EGFR monoclonal antibody therapy in RAS wild-type metastatic colorectal cancer: a systematic review and meta-analysis.
Lu X; Li Y; Li Y; Zhang X; Shi J; Feng H; Yu Z; Gao Y
BMC Cancer; 2023 Nov; 23(1):1117. PubMed ID: 37974093
[TBL] [Abstract][Full Text] [Related]
33. Development and Characterization of a Genetic Mouse Model of KRAS Mutated Colorectal Cancer.
Maitra R; Thavornwatanayong T; Venkatesh MK; Chandy C; Vachss D; Augustine T; Guzik H; Koba W; Liu Q; Goel S
Int J Mol Sci; 2019 Nov; 20(22):. PubMed ID: 31766149
[TBL] [Abstract][Full Text] [Related]
34. Targeted Inhibition of EGFR and Glutaminase Induces Metabolic Crisis in EGFR Mutant Lung Cancer.
Momcilovic M; Bailey ST; Lee JT; Fishbein MC; Magyar C; Braas D; Graeber T; Jackson NJ; Czernin J; Emberley E; Gross M; Janes J; Mackinnon A; Pan A; Rodriguez M; Works M; Zhang W; Parlati F; Demo S; Garon E; Krysan K; Walser TC; Dubinett SM; Sadeghi S; Christofk HR; Shackelford DB
Cell Rep; 2017 Jan; 18(3):601-610. PubMed ID: 28099841
[TBL] [Abstract][Full Text] [Related]
35. Dasatinib sensitizes KRAS mutant colorectal tumors to cetuximab.
Dunn EF; Iida M; Myers RA; Campbell DA; Hintz KA; Armstrong EA; Li C; Wheeler DL
Oncogene; 2011 Feb; 30(5):561-74. PubMed ID: 20956938
[TBL] [Abstract][Full Text] [Related]
36. Correlation between
Liu X; Wang SC; Ni M; Xie Q; Zhang YF; Lv WF; Geng GY
Abdom Radiol (NY); 2022 Apr; 47(4):1255-1264. PubMed ID: 35138462
[TBL] [Abstract][Full Text] [Related]
37. Heterogeneous EGFR gene copy number increase is common in colorectal cancer and defines response to anti-EGFR therapy.
Ålgars A; Avoranta T; Österlund P; Lintunen M; Sundström J; Jokilehto T; Ristimäki A; Ristamäki R; Carpén O
PLoS One; 2014; 9(6):e99590. PubMed ID: 24940619
[TBL] [Abstract][Full Text] [Related]
38. A systems mechanism for KRAS mutant allele-specific responses to targeted therapy.
McFall T; Diedrich JK; Mengistu M; Littlechild SL; Paskvan KV; Sisk-Hackworth L; Moresco JJ; Shaw AS; Stites EC
Sci Signal; 2019 Sep; 12(600):. PubMed ID: 31551296
[TBL] [Abstract][Full Text] [Related]
39. Depleting receptor tyrosine kinases EGFR and HER2 overcomes resistance to EGFR inhibitors in colorectal cancer.
Yang L; Bhattacharya A; Li Y; Sexton S; Ling X; Li F; Zhang Y
J Exp Clin Cancer Res; 2022 Jun; 41(1):184. PubMed ID: 35650607
[TBL] [Abstract][Full Text] [Related]
40. Preclinical activity of the rational combination of selumetinib (AZD6244) in combination with vorinostat in KRAS-mutant colorectal cancer models.
Morelli MP; Tentler JJ; Kulikowski GN; Tan AC; Bradshaw-Pierce EL; Pitts TM; Brown AM; Nallapareddy S; Arcaroli JJ; Serkova NJ; Hidalgo M; Ciardiello F; Eckhardt SG
Clin Cancer Res; 2012 Feb; 18(4):1051-62. PubMed ID: 22173548
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
